Supplementary Materials

Supplementary Material for:

Mechanoresponsive stem cells to target cancer metastases through biophysical cues

Linan Liu, Shirley X. Zhang, Wenbin Liao, Henry P. Farhoodi, Chi W. Wong, Claire C. Chen, Aude I. Ségaliny, Jenu V. Chacko, Lily P. Nguyen, Mengrou Lu, George Polovin, Egest J. Pone, Timothy L. Downing, Devon A. Lawson, Michelle A. Digman, Weian Zhao*

*Corresponding author. Email: weianz{at}uci.edu

Published 26 July 2017, Sci. Transl. Med. 9, eaan2966 (2017)
DOI: 10.1126/scitranslmed.aan2966

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Concept of MRCS for targeting breast cancer metastases in the lung.
  • Fig. S2. Construction of MRCS.
  • Fig. S3. MRCS-eGFP activation in response to substrate stiffness in vitro.
  • Fig. S4. MRCS-eGFP in vitro validation with immunostaining.
  • Fig. S5. Further MRCS-Luc in vitro validation.
  • Fig. S6. CD-MSC able to kill cancer cells in the presence of 5-FC in vitro.
  • Fig. S7. MRCS-CD responding to matrix stiffness in vitro.
  • Fig. S8. Bystander effect from MRCS-CD starting at 24 hours in vitro on stiff substrate.
  • Fig. S9. Bystander effect from MRCS-CD lasting after MSC removal in vitro on stiff substrate.
  • Fig. S10. Luc-MSC homing to the metastatic niche in vivo.
  • Fig. S11. MRCS homing and specific activation in response to the metastatic niche in vivo.
  • Fig. S12. Specific activation of MRCS-eGFP in response to the metastatic niche in vivo.
  • Fig. S13. MRCS-CD unable to attenuate cancer growth in the absence of 5-FC in vivo.
  • Fig. S14. No detectable side effects in bone marrow cell populations after systemic treatment with MRCS-CD.
  • Fig. S15. MRCS-CD causing no detectable side effects in vivo in bone marrow.
  • Fig. S16. MRCS-CD causing no detectable side effects in vivo in livers.
  • Fig. S17. MRCS-CD causing no detectable side effects in vivo in brains.
  • Fig. S18. Up-regulation and colocalization of LOX expression with tumor in tumor-bearing lungs.
  • Fig. S19. LOX expression up-regulated with increased collagen expression in the metastatic niche.
  • Fig. S20. SHG imaging showing up-regulated and more linearized collagen in tumor-bearing lungs.
  • Fig. S21. Split-channel views of MRCS activation in the metastatic niche in vivo.
  • Fig. S22. Cross-linking–specific tissue damage by MRCS in response to mechano-cues in the metastatic niche in vivo.
  • Fig. S23. Constitutively CD-expressing MSCs causing nonspecific tissue damage in vivo.
  • Fig. S24. Spontaneous lung metastasis model establishment.
  • Fig. S25. Split-channel views of cross-linking–specific tissue damage by MRCS in the metastatic niche in vivo in spontaneous lung metastasis model.
  • Table S1. Primary antibodies.
  • Table S2. Secondary antibodies.
  • Table S3. Primers used in qPCR.
  • References (57–68)

[Download PDF]